Skip to content

Search

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

This article discusses the relationships between gut colonization & inflammatory noncommunicable diseases, in regards to their treatment and prevention.

In-utero exposures and the evolving epidemiology of paediatric allergy

This paper discusses the rising prevalence of allergic disease in children. This review article considers recent findings in the field of paediatric immune...

Mechanisms of allergic disease - environmental and genetic determinants for the development of allergy

Environmental exposures including maternal inflammation, diet, nutrient balance, microbial colonization and toxin exposures can directly and indirectly...

Prevention and Natural History of Food Allergy

The rise in food allergy is more rapid than genetic deviation would allow and the current consensus is that environmental factors integrally linked to the...

Developing primary intervention strategies to prevent allergic disease

Allergic diseases are a major cause of morbidity in the developed world, now affecting up to 40 % of the population with no evidence that this is abating.

Blood DNA methylation biomarkers predict clinical reactivity in food-sensitized infants

The diagnosis of food allergy (FA) can be challenging because approximately half of food-sensitized patients are asymptomatic.

Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy

Peanut allergy is the the most common cause of life-threatening food-induced anaphylaxis. There is currently no effective long-term treatment. There is a pressing need for definitive treatments that improve the quality of life and prevent fatalities. Allergen oral immunotherapy (OIT) is a promising approach, which is effective at inducing desensitisation; however, OIT has a limited ability to induce sustained unresponsiveness (SU).

Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy

Peanut allergy is the the most common cause of life-threatening food-induced anaphylaxis. There is currently no effective long-term treatment. There is a pressing need for definitive treatments that improve the quality of life and prevent fatalities.

Innate immune activation occurs in acute food protein–induced enterocolitis syndrome reactions

Food reactions in food protein–induced enterocolitis syndrome are predominantly underpinned by activation of the innate immune system

Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program

Peanut allergy is the most common food allergy in Australian school-aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease-modifying treatment for food allergy, is limited in many regions of the world, including Australia.